Explore the latest scientific publications from Topas Therapeutics, showcasing our immunotherapy and immune tolerance research and innovations.
Publications
5 May 2026
Antigen-specific tolerance and control of autoimmunity effected by liver sinusoidal endothelial cells is unimpaired in liver fibrosis
12 March, 2026
Nanoparticles targeting liver sinusoidal endothelial cells improve tolerance to vector and transgene antigens through tolerance spreading
29 January 2026
Antigen-specific immune modulation with liver-targeting nanoparticles fosters immune protective regulatory T cells to delay Type 1 Diabetes
7 August, 2025
Safety, tolerability, pharmacokinetics and pharmacodynamic effects of desmoglein 3 peptide-coupled tolerizing nanoparticles in pemphigus
17 March, 2025
Nanoparticle platform preferentially targeting liver sinusoidal endothelial cells induces tolerance in CD4+ T cell-mediated disease models
7 January, 2021
Nanoparticle‐mediated targeting of autoantigen peptide to cross‐presenting liver sinusoidal endothelial cells protects from CD8 T‐cell‐driven autoimmune cholangitis
21 January, 2015
Nanoparticle-based autoantigen delivery to Treg-inducing liver sinusoidal endothelial cells enables control of autoimmunity in mice